Feedback ( (GB:FDBK) ) has shared an update.
Feedback plc has announced its half-year results, highlighting key operational and financial achievements. The company secured a significant contract with Queen Victoria Hospital NHS Foundation Trust and received additional funding to expand its community diagnostic center pilot. Feedback’s Bleepa platform was approved for reimbursement through the Elective Recovery Fund, aligning with the UK government’s focus on NHS reform and elective care. Financially, the company reported a 3% increase in revenue and a 43% rise in sales, alongside a reduced EBITDA loss. Post-period, Feedback operationalized projects in India and continued its strategic alignment with NHS England’s priorities, positioning itself for growth amid evolving market conditions.
More about Feedback
Feedback plc is a clinical infrastructure specialist that designs products to enhance clinician access to patient data and facilitate collaboration among remote clinical teams. Their products, Bleepa® and CareLocker®, work together to provide a digital infrastructure that enables clinicians to interact with patient data across multiple settings, supporting flexibility and connectivity in healthcare delivery. The company operates a scalable Software as a Service (SaaS) model, targeting growth opportunities in both domestic and international markets, including the NHS and private healthcare providers.
Average Trading Volume: 143,404
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £8M
For detailed information about FDBK stock, go to TipRanks’ Stock Analysis page.